Moderate thyroid hormone suppression therapy (THST) is associated with the best outcomes for patients with all stages of thyroid cancer, according to a prospective analysis of a multi-institutional registry published in the Journal of Clinical Endocrinology & Metabolism.

The researchers examined the outcomes of initial treatment for 4,941 patients with differentiated thyroid cancer (DTC), according to registry data from the National Thyroid Cancer Treatment Cooperative Study Group. The treatments included total/near total thyroidectomy (T/NTT), postoperative radioactive iodine-131 (¹³¹I), and THST. The median duration between treatment and follow-up for a patient was 6 years, with follow-up information available for all but 94 (1.9%) of the patients in the cohort.

Overall improvement was noted in stage III patients who received ¹³¹I (risk ratio, 0.66; P = .04) and stage IV patients who received both T/NTT and ¹³¹I (RR, 0.66; P = .049). In all stages, moderate THST was associated with significantly improved overall survival (RR stages I-IV: 0.13, 0.09, 0.13, and 0.33, respectively) and disease-free survival (DFS) (RR stages I-III: 0.52, 0.40, and 0.18, respectively); no additional survival benefit was achieved with more aggressive THST, even when distant metastatic disease was diagnosed during follow-up.

Lower initial stage and moderate THST were independent predictors of improved overall survival during follow-up years 1-3.

Consistent with previous research, this study also showed that T/NTT followed by ¹³¹I is associated with benefit in high-risk, but not low-risk patients.

“We report for the first time, in multivariate analysis of primary treatments for DTC, across all stages, only THST was associated with both improved stage-adjusted OS and DFS,” noted Dr. Aubrey A. Carhill and his colleagues.

“This analysis of the larger, more mature registry database extends and refines earlier observations regarding the impact of initial therapies on patient outcomes and further justifies the need for prospective, long-term, controlled studies,” the researchers noted.

Read the full study in the Journal of Clinical Endocrinology & Metabolism (doi:10.1210/JC.2015-1346).

[email protected]

Moderate thyroid hormone suppression therapy (THST) is associated with the best outcomes for patients with all stages of thyroid cancer, according to a prospective analysis of a multi-institutional registry published in the Journal of Clinical Endocrinology & Metabolism.

The researchers examined the outcomes of initial treatment for 4,941 patients with differentiated thyroid cancer (DTC), according to registry data from the National Thyroid Cancer Treatment Cooperative Study Group. The treatments included total/near total thyroidectomy (T/NTT), postoperative radioactive iodine-131 (¹³¹I), and THST. The median duration between treatment and follow-up for a patient was 6 years, with follow-up information available for all but 94 (1.9%) of the patients in the cohort.

Overall improvement was noted in stage III patients who received ¹³¹I (risk ratio, 0.66; P = .04) and stage IV patients who received both T/NTT and ¹³¹I (RR, 0.66; P = .049). In all stages, moderate THST was associated with significantly improved overall survival (RR stages I-IV: 0.13, 0.09, 0.13, and 0.33, respectively) and disease-free survival (DFS) (RR stages I-III: 0.52, 0.40, and 0.18, respectively); no additional survival benefit was achieved with more aggressive THST, even when distant metastatic disease was diagnosed during follow-up.

Lower initial stage and moderate THST were independent predictors of improved overall survival during follow-up years 1-3.

Consistent with previous research, this study also showed that T/NTT followed by ¹³¹I is associated with benefit in high-risk, but not low-risk patients.

“We report for the first time, in multivariate analysis of primary treatments for DTC, across all stages, only THST was associated with both improved stage-adjusted OS and DFS,” noted Dr. Aubrey A. Carhill and his colleagues.

“This analysis of the larger, more mature registry database extends and refines earlier observations regarding the impact of initial therapies on patient outcomes and further justifies the need for prospective, long-term, controlled studies,” the researchers noted.

Read the full study in the Journal of Clinical Endocrinology & Metabolism (doi:10.1210/JC.2015-1346).

[email protected]

Moderate thyroid hormone suppression therapy (THST) is associated with the best outcomes for patients with all stages of thyroid cancer, according to a prospective analysis of a multi-institutional registry published in the Journal of Clinical Endocrinology & Metabolism.

The researchers examined the outcomes of initial treatment for 4,941 patients with differentiated thyroid cancer (DTC), according to registry data from the National Thyroid Cancer Treatment Cooperative Study Group. The treatments included total/near total thyroidectomy (T/NTT), postoperative radioactive iodine-131 (¹³¹I), and THST. The median duration between treatment and follow-up for a patient was 6 years, with follow-up information available for all but 94 (1.9%) of the patients in the cohort.

Overall improvement was noted in stage III patients who received ¹³¹I (risk ratio, 0.66; P = .04) and stage IV patients who received both T/NTT and ¹³¹I (RR, 0.66; P = .049). In all stages, moderate THST was associated with significantly improved overall survival (RR stages I-IV: 0.13, 0.09, 0.13, and 0.33, respectively) and disease-free survival (DFS) (RR stages I-III: 0.52, 0.40, and 0.18, respectively); no additional survival benefit was achieved with more aggressive THST, even when distant metastatic disease was diagnosed during follow-up.

Lower initial stage and moderate THST were independent predictors of improved overall survival during follow-up years 1-3.

Consistent with previous research, this study also showed that T/NTT followed by ¹³¹I is associated with benefit in high-risk, but not low-risk patients.

“We report for the first time, in multivariate analysis of primary treatments for DTC, across all stages, only THST was associated with both improved stage-adjusted OS and DFS,” noted Dr. Aubrey A. Carhill and his colleagues.

“This analysis of the larger, more mature registry database extends and refines earlier observations regarding the impact of initial therapies on patient outcomes and further justifies the need for prospective, long-term, controlled studies,” the researchers noted.

Read the full study in the Journal of Clinical Endocrinology & Metabolism (doi:10.1210/JC.2015-1346).

[email protected]

Duchenne muscular dystrophy (DMD), an X-linked condition, is the most common muscular dystrophy in children and affects families of all ethnicities. Incidence is about 1 in 3,500 boys. Approximately two-thirds of clinically diagnosed cases of DMD are attributable to a carrier mother, who is likely unaware that she is a carrier. In addition to providing information about reproductive risks, carrier screening can identify women who are, themselves, at risk of health effects caused by defects in the DMD gene.

This supplement examines the latest crucial advances in DMD carrier screening.

Click here to download the PDF.

To view an exclusive video on the pivotal findings discussed in this supplement, click here.

Duchenne muscular dystrophy (DMD), an X-linked condition, is the most common muscular dystrophy in children and affects families of all ethnicities. Incidence is about 1 in 3,500 boys. Approximately two-thirds of clinically diagnosed cases of DMD are attributable to a carrier mother, who is likely unaware that she is a carrier. In addition to providing information about reproductive risks, carrier screening can identify women who are, themselves, at risk of health effects caused by defects in the DMD gene.

This supplement examines the latest crucial advances in DMD carrier screening.

Click here to download the PDF.

To view an exclusive video on the pivotal findings discussed in this supplement, click here.

Duchenne muscular dystrophy (DMD), an X-linked condition, is the most common muscular dystrophy in children and affects families of all ethnicities. Incidence is about 1 in 3,500 boys. Approximately two-thirds of clinically diagnosed cases of DMD are attributable to a carrier mother, who is likely unaware that she is a carrier. In addition to providing information about reproductive risks, carrier screening can identify women who are, themselves, at risk of health effects caused by defects in the DMD gene.

This supplement examines the latest crucial advances in DMD carrier screening.

Click here to download the PDF.

To view an exclusive video on the pivotal findings discussed in this supplement, click here.

Half of moderate to severe traumatic brain injury patients had markedly impaired corpus callosum (CC) functioning and structural integrity that is associated with poor neurocognitive functioning, according to a study of children aged 8-19 years.

The researchers used high angular resolution diffusion-weighted imaging to determine the structural integrities of the CC in 32 children who had suffered a traumatic brain injury (TBI) and of the CC in 31 healthy children. Patients in the experimental group had suffered from a moderate to severe TBI 1-5 months prior to the study. The researchers assessed CC function through interhemispheric transfer time (IHTT) – the time required to transfer stimulus-locked neural activity between the left and right brain hemispheres. Each participant’s IHTT was calculated from recording electroencephalography, while he or she completed a computerized, pattern-matching task with bilateral field advantage.

Half of the TBI patients had significantly slower IHTTs than did the control group. The IHTTs of this so-called IHTT-slow TBI group deviated by at least 1.5 standard deviations from data for the healthy control group.

The IHTT-slow TBI group also demonstrated lower CC integrity and poorer neurocognitive functioning than did both the control group and the remaining members of the experimental group. Lower fractional anisotropy (FA) – a common sign of impaired white matter (WM) – and slower IHTTs also predicted poor neurocognitive function.

“When we compared the IHTT-slow TBI group to the healthy control group, we found significant differences in callosal WM integrity, as well as the integrity of the association and projection tract systems tested. Lower FA and higher mean diffusivity (MD) in the IHTT-slow group suggests myelin disruption,” noted Emily L Dennis of the University of Southern California, Marina del Rey, and her colleagues. “When we compared the IHTT-normal TBI group to the healthy control group, we found only a few areas where the TBI group had significantly lower FA and no significant differences in MD [mean diffusivity].”

Read the full study in the Journal of Neuroscience (doi:10.1523/JNEUROSCI.1595-15.2015).

[email protected]

Half of moderate to severe traumatic brain injury patients had markedly impaired corpus callosum (CC) functioning and structural integrity that is associated with poor neurocognitive functioning, according to a study of children aged 8-19 years.

The researchers used high angular resolution diffusion-weighted imaging to determine the structural integrities of the CC in 32 children who had suffered a traumatic brain injury (TBI) and of the CC in 31 healthy children. Patients in the experimental group had suffered from a moderate to severe TBI 1-5 months prior to the study. The researchers assessed CC function through interhemispheric transfer time (IHTT) – the time required to transfer stimulus-locked neural activity between the left and right brain hemispheres. Each participant’s IHTT was calculated from recording electroencephalography, while he or she completed a computerized, pattern-matching task with bilateral field advantage.

Half of the TBI patients had significantly slower IHTTs than did the control group. The IHTTs of this so-called IHTT-slow TBI group deviated by at least 1.5 standard deviations from data for the healthy control group.

The IHTT-slow TBI group also demonstrated lower CC integrity and poorer neurocognitive functioning than did both the control group and the remaining members of the experimental group. Lower fractional anisotropy (FA) – a common sign of impaired white matter (WM) – and slower IHTTs also predicted poor neurocognitive function.

“When we compared the IHTT-slow TBI group to the healthy control group, we found significant differences in callosal WM integrity, as well as the integrity of the association and projection tract systems tested. Lower FA and higher mean diffusivity (MD) in the IHTT-slow group suggests myelin disruption,” noted Emily L Dennis of the University of Southern California, Marina del Rey, and her colleagues. “When we compared the IHTT-normal TBI group to the healthy control group, we found only a few areas where the TBI group had significantly lower FA and no significant differences in MD [mean diffusivity].”

Read the full study in the Journal of Neuroscience (doi:10.1523/JNEUROSCI.1595-15.2015).

[email protected]

Half of moderate to severe traumatic brain injury patients had markedly impaired corpus callosum (CC) functioning and structural integrity that is associated with poor neurocognitive functioning, according to a study of children aged 8-19 years.

The researchers used high angular resolution diffusion-weighted imaging to determine the structural integrities of the CC in 32 children who had suffered a traumatic brain injury (TBI) and of the CC in 31 healthy children. Patients in the experimental group had suffered from a moderate to severe TBI 1-5 months prior to the study. The researchers assessed CC function through interhemispheric transfer time (IHTT) – the time required to transfer stimulus-locked neural activity between the left and right brain hemispheres. Each participant’s IHTT was calculated from recording electroencephalography, while he or she completed a computerized, pattern-matching task with bilateral field advantage.

Half of the TBI patients had significantly slower IHTTs than did the control group. The IHTTs of this so-called IHTT-slow TBI group deviated by at least 1.5 standard deviations from data for the healthy control group.

The IHTT-slow TBI group also demonstrated lower CC integrity and poorer neurocognitive functioning than did both the control group and the remaining members of the experimental group. Lower fractional anisotropy (FA) – a common sign of impaired white matter (WM) – and slower IHTTs also predicted poor neurocognitive function.

“When we compared the IHTT-slow TBI group to the healthy control group, we found significant differences in callosal WM integrity, as well as the integrity of the association and projection tract systems tested. Lower FA and higher mean diffusivity (MD) in the IHTT-slow group suggests myelin disruption,” noted Emily L Dennis of the University of Southern California, Marina del Rey, and her colleagues. “When we compared the IHTT-normal TBI group to the healthy control group, we found only a few areas where the TBI group had significantly lower FA and no significant differences in MD [mean diffusivity].”

Read the full study in the Journal of Neuroscience (doi:10.1523/JNEUROSCI.1595-15.2015).

[email protected]

At the insistence of his wife, a 39-year-old man presents to dermatology for evaluation of a lesion on his neck that manifested three years ago. As the lesion has grown, darkened, and become more irregular in outline, she has urged him to have it checked. Her efforts finally succeeded when several of his coworkers also commented on it.

The patient has a history of sun exposure but says he tolerates it well and tans easily. He is otherwise healthy.

EXAMINATION
The irregularly pigmented and bordered dark brown macule, located on the lateral aspect of the left side of his neck,  measures about 2 cm in its greatest dimension. The rest of his neck shows definite signs of chronic UV overexposure, in the form of poikilodermatous changes.

Dermatoscopic examination of the lesion shows focal areas of pigment streaming and blue veiling—both indicative of melanoma. In light of these findings and in the context of his heavily sun-damaged skin, the patient is scheduled for excision. This is performed one week later; the lesion is removed with 5-mm margins, producing a curved, elliptiform defect to match local skin lines, with a two-layer closure.

What is the diagnosis?

DISCUSSION
The pathology report showed the lesion to be an early lentigo maligna (LM). Most authorities in the field do not consider this a true melanoma, although it is probably best considered a type of melanoma in situ. LM definitely involves cellular atypia, but at a very superficial level. Only a tiny fraction of LMs ever become invasive—and only after several years of being left in place.

LM isn’t always as obvious as this patient’s lesion is. It can be brown, red, or even bluish and can blend into surrounding mottled skin lesions (eg, solar lentigines, seborrheic keratoses or actinic keratosis). The key to diagnosis is to observe for change in size and/or color, especially on sun-exposed areas of skin in older, sun-damaged patients.

In this case, the decision to excise the lesion was made easier by its size and location. Larger lesions of uncertain dimensions may be assessed with multiple punch biopsies.

Once LM is diagnosed, the problem becomes obtaining adequate margins surgically, given the often ill-defined dimensions of the lesion. Failure rates, even when Mohs surgery is performed, are all too high. Surgery has therefore been combined with the application of immune-enhancing creams (eg, imiquimod), a method that shows promise but yields conflicting results in studies.

Since many LMs appear on truly elderly patients, and since their evolution to invasive status is so slow, they don’t command the same urgency as a truly invasive melanoma. Clinically, however, this patient’s lesion met the criteria by which we judge potentially malignant lesions: asymmetry, irregular borders, odd color, and large size. It could easily have been an invasive melanoma, either at the time or in future. Finding and identifying it not only delivered peace of mind but also provided a warning that the patient had some serious sun damage—and therefore the potential to develop other cutaneous malignancies.

Fortunately, a whole-body check revealed no other worrisome lesions. The patient has, however, been scheduled for twice-yearly skin checks. He also received education on the recognition of melanoma.

TAKE-HOME LEARNING POINTS
• The prognosis for a melanoma is determined by numerous factors, most notably the vertical thickness of the lesion, as measured under the microscope by the examining pathologist.

• The lentigo maligna lesion, as seen in this case, can be so thin and superficial that some experts don’t consider it a true melanoma.

• Nonetheless, the gross appearance of such lesions typifies the main diagnostic features (ABCDs) of melanoma: Asymmetry, odd Borders, odd Colors, and Diameter (large size).

• The finding of an LM means the patient has increased risk for invasive melanoma in the future.

At the insistence of his wife, a 39-year-old man presents to dermatology for evaluation of a lesion on his neck that manifested three years ago. As the lesion has grown, darkened, and become more irregular in outline, she has urged him to have it checked. Her efforts finally succeeded when several of his coworkers also commented on it.

The patient has a history of sun exposure but says he tolerates it well and tans easily. He is otherwise healthy.

EXAMINATION
The irregularly pigmented and bordered dark brown macule, located on the lateral aspect of the left side of his neck,  measures about 2 cm in its greatest dimension. The rest of his neck shows definite signs of chronic UV overexposure, in the form of poikilodermatous changes.

Dermatoscopic examination of the lesion shows focal areas of pigment streaming and blue veiling—both indicative of melanoma. In light of these findings and in the context of his heavily sun-damaged skin, the patient is scheduled for excision. This is performed one week later; the lesion is removed with 5-mm margins, producing a curved, elliptiform defect to match local skin lines, with a two-layer closure.

What is the diagnosis?

DISCUSSION
The pathology report showed the lesion to be an early lentigo maligna (LM). Most authorities in the field do not consider this a true melanoma, although it is probably best considered a type of melanoma in situ. LM definitely involves cellular atypia, but at a very superficial level. Only a tiny fraction of LMs ever become invasive—and only after several years of being left in place.

LM isn’t always as obvious as this patient’s lesion is. It can be brown, red, or even bluish and can blend into surrounding mottled skin lesions (eg, solar lentigines, seborrheic keratoses or actinic keratosis). The key to diagnosis is to observe for change in size and/or color, especially on sun-exposed areas of skin in older, sun-damaged patients.

In this case, the decision to excise the lesion was made easier by its size and location. Larger lesions of uncertain dimensions may be assessed with multiple punch biopsies.

Once LM is diagnosed, the problem becomes obtaining adequate margins surgically, given the often ill-defined dimensions of the lesion. Failure rates, even when Mohs surgery is performed, are all too high. Surgery has therefore been combined with the application of immune-enhancing creams (eg, imiquimod), a method that shows promise but yields conflicting results in studies.

Since many LMs appear on truly elderly patients, and since their evolution to invasive status is so slow, they don’t command the same urgency as a truly invasive melanoma. Clinically, however, this patient’s lesion met the criteria by which we judge potentially malignant lesions: asymmetry, irregular borders, odd color, and large size. It could easily have been an invasive melanoma, either at the time or in future. Finding and identifying it not only delivered peace of mind but also provided a warning that the patient had some serious sun damage—and therefore the potential to develop other cutaneous malignancies.

Fortunately, a whole-body check revealed no other worrisome lesions. The patient has, however, been scheduled for twice-yearly skin checks. He also received education on the recognition of melanoma.

TAKE-HOME LEARNING POINTS
• The prognosis for a melanoma is determined by numerous factors, most notably the vertical thickness of the lesion, as measured under the microscope by the examining pathologist.

• The lentigo maligna lesion, as seen in this case, can be so thin and superficial that some experts don’t consider it a true melanoma.

• Nonetheless, the gross appearance of such lesions typifies the main diagnostic features (ABCDs) of melanoma: Asymmetry, odd Borders, odd Colors, and Diameter (large size).

• The finding of an LM means the patient has increased risk for invasive melanoma in the future.

At the insistence of his wife, a 39-year-old man presents to dermatology for evaluation of a lesion on his neck that manifested three years ago. As the lesion has grown, darkened, and become more irregular in outline, she has urged him to have it checked. Her efforts finally succeeded when several of his coworkers also commented on it.

The patient has a history of sun exposure but says he tolerates it well and tans easily. He is otherwise healthy.

EXAMINATION
The irregularly pigmented and bordered dark brown macule, located on the lateral aspect of the left side of his neck,  measures about 2 cm in its greatest dimension. The rest of his neck shows definite signs of chronic UV overexposure, in the form of poikilodermatous changes.

Dermatoscopic examination of the lesion shows focal areas of pigment streaming and blue veiling—both indicative of melanoma. In light of these findings and in the context of his heavily sun-damaged skin, the patient is scheduled for excision. This is performed one week later; the lesion is removed with 5-mm margins, producing a curved, elliptiform defect to match local skin lines, with a two-layer closure.

What is the diagnosis?

DISCUSSION
The pathology report showed the lesion to be an early lentigo maligna (LM). Most authorities in the field do not consider this a true melanoma, although it is probably best considered a type of melanoma in situ. LM definitely involves cellular atypia, but at a very superficial level. Only a tiny fraction of LMs ever become invasive—and only after several years of being left in place.

LM isn’t always as obvious as this patient’s lesion is. It can be brown, red, or even bluish and can blend into surrounding mottled skin lesions (eg, solar lentigines, seborrheic keratoses or actinic keratosis). The key to diagnosis is to observe for change in size and/or color, especially on sun-exposed areas of skin in older, sun-damaged patients.

In this case, the decision to excise the lesion was made easier by its size and location. Larger lesions of uncertain dimensions may be assessed with multiple punch biopsies.

Once LM is diagnosed, the problem becomes obtaining adequate margins surgically, given the often ill-defined dimensions of the lesion. Failure rates, even when Mohs surgery is performed, are all too high. Surgery has therefore been combined with the application of immune-enhancing creams (eg, imiquimod), a method that shows promise but yields conflicting results in studies.

Since many LMs appear on truly elderly patients, and since their evolution to invasive status is so slow, they don’t command the same urgency as a truly invasive melanoma. Clinically, however, this patient’s lesion met the criteria by which we judge potentially malignant lesions: asymmetry, irregular borders, odd color, and large size. It could easily have been an invasive melanoma, either at the time or in future. Finding and identifying it not only delivered peace of mind but also provided a warning that the patient had some serious sun damage—and therefore the potential to develop other cutaneous malignancies.

Fortunately, a whole-body check revealed no other worrisome lesions. The patient has, however, been scheduled for twice-yearly skin checks. He also received education on the recognition of melanoma.

TAKE-HOME LEARNING POINTS
• The prognosis for a melanoma is determined by numerous factors, most notably the vertical thickness of the lesion, as measured under the microscope by the examining pathologist.

• The lentigo maligna lesion, as seen in this case, can be so thin and superficial that some experts don’t consider it a true melanoma.

• Nonetheless, the gross appearance of such lesions typifies the main diagnostic features (ABCDs) of melanoma: Asymmetry, odd Borders, odd Colors, and Diameter (large size).

• The finding of an LM means the patient has increased risk for invasive melanoma in the future.

I have been a traveling road show for the last 2 years, explaining the value of dermatology to insurers. It is amazing how poorly understood we are by payers.

Let me give you an example. Currently, dermatologists treat about 70% of all skin cancers. This is up from the 10% we treated 30 years ago, but if you think about it, it should be 98% or 99%. There were 5.4 million skin cancers in the United States in 2012. The great majority were nonmelanoma skin cancers (at an interesting ratio of 1:1 for basal cell carcinoma and squamous cell carcinoma), and only about 75,000 were melanomas. About 80% of all melanomas are less than 1 mm in thickness and undoubtedly appropriate for local excision in the office. Dermatologists treat these skin cancers at less than ¹/₅ the cost of treatment in a facility. We, and a few primary care physicians, are the only physicians who are not operating room dependent. We can remove these cancers under local anesthesia in the office, without an anesthesiologist, multiple nurses, intravenous lines, preop labs, and the other high fixed costs associated with a hospital procedure, and we can do it promptly. Insurers should be pounding their drums to demand that the vast majority of skin cancers be treated in the office setting, rather than in a hospital. Maybe all skin cancer patients should be required to get “precertified” by a dermatologist before they are sent to a hospital for a procedure. This would improve quality and greatly cut costs.

Insurers always drop their jaws when I explain this to them. They have never matched up the costs of the physicians and the costs of the facilities where procedures are performed. They need to consider the value of the dermatologist in providing an accurate, quick diagnosis, with immediate exclusion of benign lesions and elimination of the long wait times to get a cancer removed. It costs less to get a skin cancer diagnosed and removed by a dermatologist than to get a new set of car tires installed, and we can often do it in about the same amount of time. Compare that with $150,000 spent annually to treat metastatic melanoma.

In addition, fewer dermatologists mean longer wait times to see the dermatologist, causing what I call the “spillover” effect. When patients cannot get in to see the dermatologist, they call their primary care physician, who sends them down to the hospital to see their general surgeon on lumps and bumps day. Everything gets removed, benign or not, in the hospital outpatient department.

That is why it is insane for insurers to be eliminating dermatologists wholesale from their “tight” networks. Their software tells them they will save money in the short term, but they won’t because of the spillover, and it is very foolish in the long term. With the advent of the Affordable Care Act, patients cannot be excluded for preexisting conditions, and these patients all become long-term clients of one insurer or another. What is neglected today becomes a nightmare tomorrow. Dermatology offers an extraordinarily high value quotient, but only if insurers have enough sense to let the patients see us.

Dr. Coldiron is in private practice, but maintains a clinical assistant professorship of dermatology at the University of Cincinnati. Email him at [email protected].

I have been a traveling road show for the last 2 years, explaining the value of dermatology to insurers. It is amazing how poorly understood we are by payers.

Let me give you an example. Currently, dermatologists treat about 70% of all skin cancers. This is up from the 10% we treated 30 years ago, but if you think about it, it should be 98% or 99%. There were 5.4 million skin cancers in the United States in 2012. The great majority were nonmelanoma skin cancers (at an interesting ratio of 1:1 for basal cell carcinoma and squamous cell carcinoma), and only about 75,000 were melanomas. About 80% of all melanomas are less than 1 mm in thickness and undoubtedly appropriate for local excision in the office. Dermatologists treat these skin cancers at less than ¹/₅ the cost of treatment in a facility. We, and a few primary care physicians, are the only physicians who are not operating room dependent. We can remove these cancers under local anesthesia in the office, without an anesthesiologist, multiple nurses, intravenous lines, preop labs, and the other high fixed costs associated with a hospital procedure, and we can do it promptly. Insurers should be pounding their drums to demand that the vast majority of skin cancers be treated in the office setting, rather than in a hospital. Maybe all skin cancer patients should be required to get “precertified” by a dermatologist before they are sent to a hospital for a procedure. This would improve quality and greatly cut costs.

Insurers always drop their jaws when I explain this to them. They have never matched up the costs of the physicians and the costs of the facilities where procedures are performed. They need to consider the value of the dermatologist in providing an accurate, quick diagnosis, with immediate exclusion of benign lesions and elimination of the long wait times to get a cancer removed. It costs less to get a skin cancer diagnosed and removed by a dermatologist than to get a new set of car tires installed, and we can often do it in about the same amount of time. Compare that with $150,000 spent annually to treat metastatic melanoma.

In addition, fewer dermatologists mean longer wait times to see the dermatologist, causing what I call the “spillover” effect. When patients cannot get in to see the dermatologist, they call their primary care physician, who sends them down to the hospital to see their general surgeon on lumps and bumps day. Everything gets removed, benign or not, in the hospital outpatient department.

That is why it is insane for insurers to be eliminating dermatologists wholesale from their “tight” networks. Their software tells them they will save money in the short term, but they won’t because of the spillover, and it is very foolish in the long term. With the advent of the Affordable Care Act, patients cannot be excluded for preexisting conditions, and these patients all become long-term clients of one insurer or another. What is neglected today becomes a nightmare tomorrow. Dermatology offers an extraordinarily high value quotient, but only if insurers have enough sense to let the patients see us.

Dr. Coldiron is in private practice, but maintains a clinical assistant professorship of dermatology at the University of Cincinnati. Email him at [email protected].

I have been a traveling road show for the last 2 years, explaining the value of dermatology to insurers. It is amazing how poorly understood we are by payers.

Let me give you an example. Currently, dermatologists treat about 70% of all skin cancers. This is up from the 10% we treated 30 years ago, but if you think about it, it should be 98% or 99%. There were 5.4 million skin cancers in the United States in 2012. The great majority were nonmelanoma skin cancers (at an interesting ratio of 1:1 for basal cell carcinoma and squamous cell carcinoma), and only about 75,000 were melanomas. About 80% of all melanomas are less than 1 mm in thickness and undoubtedly appropriate for local excision in the office. Dermatologists treat these skin cancers at less than ¹/₅ the cost of treatment in a facility. We, and a few primary care physicians, are the only physicians who are not operating room dependent. We can remove these cancers under local anesthesia in the office, without an anesthesiologist, multiple nurses, intravenous lines, preop labs, and the other high fixed costs associated with a hospital procedure, and we can do it promptly. Insurers should be pounding their drums to demand that the vast majority of skin cancers be treated in the office setting, rather than in a hospital. Maybe all skin cancer patients should be required to get “precertified” by a dermatologist before they are sent to a hospital for a procedure. This would improve quality and greatly cut costs.

Insurers always drop their jaws when I explain this to them. They have never matched up the costs of the physicians and the costs of the facilities where procedures are performed. They need to consider the value of the dermatologist in providing an accurate, quick diagnosis, with immediate exclusion of benign lesions and elimination of the long wait times to get a cancer removed. It costs less to get a skin cancer diagnosed and removed by a dermatologist than to get a new set of car tires installed, and we can often do it in about the same amount of time. Compare that with $150,000 spent annually to treat metastatic melanoma.

In addition, fewer dermatologists mean longer wait times to see the dermatologist, causing what I call the “spillover” effect. When patients cannot get in to see the dermatologist, they call their primary care physician, who sends them down to the hospital to see their general surgeon on lumps and bumps day. Everything gets removed, benign or not, in the hospital outpatient department.

That is why it is insane for insurers to be eliminating dermatologists wholesale from their “tight” networks. Their software tells them they will save money in the short term, but they won’t because of the spillover, and it is very foolish in the long term. With the advent of the Affordable Care Act, patients cannot be excluded for preexisting conditions, and these patients all become long-term clients of one insurer or another. What is neglected today becomes a nightmare tomorrow. Dermatology offers an extraordinarily high value quotient, but only if insurers have enough sense to let the patients see us.

Dr. Coldiron is in private practice, but maintains a clinical assistant professorship of dermatology at the University of Cincinnati. Email him at [email protected].

Prescription medications

Photo courtesy of the CDC

Patients admitted to the emergency department (ED) for venous thromboembolism (VTE) can be placed on oral anticoagulation and discharged immediately, according to research published in Academic Emergency Medicine.

The study showed that patients who received anticoagulation with rivaroxaban, were discharged from the ED right away, and did not undergo weekly monitoring had a low rate of VTE recurrence and major or clinically relevant bleeding.

A related study suggested this approach was less costly than standard treatment with heparin and warfarin.

The prospect of being able to send patients home from the ED on the day of admission is a quality of life issue, according to Jeffrey A. Kline, MD, a professor at the Indiana University School of Medicine in Indianapolis and an author of both studies.

“We really do empower the patient more with [rivaroxaban],” he said. “Patients say treatment with no injections is a much better option. [Rivaroxaban] takes a condition that is life-threatening and makes it something the patient can control.”

Safety and efficacy

For the first study, Dr Kline and his colleagues evaluated 106 low-risk patients who were diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE) at 2 metropolitan EDs.

The patients were admitted between March 2013 and April 2014. Seventy-one patients had DVT, 30 had PE, and 5 had both.

The standard of care for these patients is heparin injections, followed by oral warfarin and close monitoring to ensure safe dosage levels.

But patients in this study received rivaroxaban, which does not require blood monitoring, and were released from the hospital on the day of admission. The patients did undergo follow up-monitoring at 2 weeks, 5 weeks, 3 months, and 6 months.

The researchers followed patients for a mean of 389 days (range, 213 to 594 days). None of the patients had a VTE recurrence, major bleeding, or clinically relevant bleeding while on therapy.

However, 3 patients (2.8%) experienced DVT recurrence within a year of stopping treatment. All 3 had completed their prescribed treatment.

“This study is about giving patients a new option,” Dr Kline said. “Treating patients at home for blood clots was found to have fewer errors than the standard of care and better outcomes. Patients [receiving standard therapy] have to be taught to give themselves injections, and it scares them to death. Almost everyone has taken a pill, so there is no learning curve for patients [with rivaroxaban].”

Treatment costs

In the second study, Dr Kline and his colleagues compared costs associated with standard treatment and rivaroxaban. Total hospital charges with the rivaroxaban protocol were about half the cost of charges for standard therapy.

The researchers evaluated 97 patients, matching them for age, sex, and the severity of their illness. At 6 months after ED admission, the median cost was $4787 (interquartile range=$3042 to $7596) for the rivaroxaban group and $11,128 (interquartile range=$8110 to $23,390) for the group treated with standard care (P<0.001).

Among patients with PE, costs were 57% lower in the rivaroxaban group than the standard therapy group (P<0.001). For patients with DVT, costs were 56% lower in the rivaroxaban group (P=0.003).

Prescription medications

Photo courtesy of the CDC

Patients admitted to the emergency department (ED) for venous thromboembolism (VTE) can be placed on oral anticoagulation and discharged immediately, according to research published in Academic Emergency Medicine.

The study showed that patients who received anticoagulation with rivaroxaban, were discharged from the ED right away, and did not undergo weekly monitoring had a low rate of VTE recurrence and major or clinically relevant bleeding.

A related study suggested this approach was less costly than standard treatment with heparin and warfarin.

The prospect of being able to send patients home from the ED on the day of admission is a quality of life issue, according to Jeffrey A. Kline, MD, a professor at the Indiana University School of Medicine in Indianapolis and an author of both studies.

“We really do empower the patient more with [rivaroxaban],” he said. “Patients say treatment with no injections is a much better option. [Rivaroxaban] takes a condition that is life-threatening and makes it something the patient can control.”

Safety and efficacy

For the first study, Dr Kline and his colleagues evaluated 106 low-risk patients who were diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE) at 2 metropolitan EDs.

The patients were admitted between March 2013 and April 2014. Seventy-one patients had DVT, 30 had PE, and 5 had both.

The standard of care for these patients is heparin injections, followed by oral warfarin and close monitoring to ensure safe dosage levels.

But patients in this study received rivaroxaban, which does not require blood monitoring, and were released from the hospital on the day of admission. The patients did undergo follow up-monitoring at 2 weeks, 5 weeks, 3 months, and 6 months.

The researchers followed patients for a mean of 389 days (range, 213 to 594 days). None of the patients had a VTE recurrence, major bleeding, or clinically relevant bleeding while on therapy.

However, 3 patients (2.8%) experienced DVT recurrence within a year of stopping treatment. All 3 had completed their prescribed treatment.

“This study is about giving patients a new option,” Dr Kline said. “Treating patients at home for blood clots was found to have fewer errors than the standard of care and better outcomes. Patients [receiving standard therapy] have to be taught to give themselves injections, and it scares them to death. Almost everyone has taken a pill, so there is no learning curve for patients [with rivaroxaban].”

Treatment costs

In the second study, Dr Kline and his colleagues compared costs associated with standard treatment and rivaroxaban. Total hospital charges with the rivaroxaban protocol were about half the cost of charges for standard therapy.

The researchers evaluated 97 patients, matching them for age, sex, and the severity of their illness. At 6 months after ED admission, the median cost was $4787 (interquartile range=$3042 to $7596) for the rivaroxaban group and $11,128 (interquartile range=$8110 to $23,390) for the group treated with standard care (P<0.001).

Among patients with PE, costs were 57% lower in the rivaroxaban group than the standard therapy group (P<0.001). For patients with DVT, costs were 56% lower in the rivaroxaban group (P=0.003).

Prescription medications

Photo courtesy of the CDC

Patients admitted to the emergency department (ED) for venous thromboembolism (VTE) can be placed on oral anticoagulation and discharged immediately, according to research published in Academic Emergency Medicine.

The study showed that patients who received anticoagulation with rivaroxaban, were discharged from the ED right away, and did not undergo weekly monitoring had a low rate of VTE recurrence and major or clinically relevant bleeding.

A related study suggested this approach was less costly than standard treatment with heparin and warfarin.

The prospect of being able to send patients home from the ED on the day of admission is a quality of life issue, according to Jeffrey A. Kline, MD, a professor at the Indiana University School of Medicine in Indianapolis and an author of both studies.

“We really do empower the patient more with [rivaroxaban],” he said. “Patients say treatment with no injections is a much better option. [Rivaroxaban] takes a condition that is life-threatening and makes it something the patient can control.”

Safety and efficacy

For the first study, Dr Kline and his colleagues evaluated 106 low-risk patients who were diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE) at 2 metropolitan EDs.

The patients were admitted between March 2013 and April 2014. Seventy-one patients had DVT, 30 had PE, and 5 had both.

The standard of care for these patients is heparin injections, followed by oral warfarin and close monitoring to ensure safe dosage levels.

But patients in this study received rivaroxaban, which does not require blood monitoring, and were released from the hospital on the day of admission. The patients did undergo follow up-monitoring at 2 weeks, 5 weeks, 3 months, and 6 months.

The researchers followed patients for a mean of 389 days (range, 213 to 594 days). None of the patients had a VTE recurrence, major bleeding, or clinically relevant bleeding while on therapy.

However, 3 patients (2.8%) experienced DVT recurrence within a year of stopping treatment. All 3 had completed their prescribed treatment.

“This study is about giving patients a new option,” Dr Kline said. “Treating patients at home for blood clots was found to have fewer errors than the standard of care and better outcomes. Patients [receiving standard therapy] have to be taught to give themselves injections, and it scares them to death. Almost everyone has taken a pill, so there is no learning curve for patients [with rivaroxaban].”

Treatment costs

In the second study, Dr Kline and his colleagues compared costs associated with standard treatment and rivaroxaban. Total hospital charges with the rivaroxaban protocol were about half the cost of charges for standard therapy.

The researchers evaluated 97 patients, matching them for age, sex, and the severity of their illness. At 6 months after ED admission, the median cost was $4787 (interquartile range=$3042 to $7596) for the rivaroxaban group and $11,128 (interquartile range=$8110 to $23,390) for the group treated with standard care (P<0.001).

Among patients with PE, costs were 57% lower in the rivaroxaban group than the standard therapy group (P<0.001). For patients with DVT, costs were 56% lower in the rivaroxaban group (P=0.003).

Patient receiving chemotherapy

Photo by Rhoda Baer

New research suggests the polyphenols resveratrol and quercetin could be used to augment treatment with the anthracycline doxorubicin.

Investigators found they could increase the bioavailability of resveratrol and quercetin using copolymers that make the compounds water soluble and allow for their injection into the blood stream.

The team then showed the compounds synergize with doxorubicin while also reducing cardiac toxicity.

Although doxorubicin has proven effective against lymphomas, leukemias, and other cancers, the drug can only be used for a limited time because it confers cardiotoxicity.

The co-administration of resveratrol and quercetin might allow for much more extensive use of doxorubicin, while at the same time improving its efficacy and demonstrating the polyphenols’ own anticancer properties, investigators said.

They described research supporting this idea in the Journal of Controlled Release.

“This has great potential to improve chemotherapeutic cancer treatment,” said Adam Alani, PhD, of Oregon State University in Portland.

“The co-administration of high levels of resveratrol and quercetin, in both in vitro and in vivo studies, shows that it significantly reduces the cardiac toxicity of [doxorubicin]. And these compounds have a synergistic effect that enhances the efficacy of the cancer drug, by sensitizing the cancer cells to the effects of the drug.”

Dr Alani said further research may demonstrate that these compounds can completely eliminate the cardiotoxicity of doxorubicin, as they scavenge the toxic free radicals produced by this drug.

It’s also possible, he said, that administration of these natural polyphenols could have value in cancer therapy by themselves or in combination with a wider range of other chemotherapeutic drugs.

Increasing bioavailability

Resveratrol is a natural compound found in foods such as grapes, red wine, green tea, berries, and dark chocolate. Quercetin reaches some of its highest natural levels in capers, some berries, and leafy greens.

When consumed via food or taken as supplements, these polyphenol compounds reach only a tiny fraction of the level that’s possible with direct injection. Such injection was not possible until Dr Alani and his colleagues adapted the use of polymeric micelles.

Specifically, the investigators combined resveratrol and quercetin in Pluronic F127 micelles (mRQ). Pluronics are triblock copolymers consisting of a polypropylene oxide chain flanked with 2 polyethylene oxide chains that can self-assemble into polymeric micelles. The micelles have hydrophobic cores that help solubilize compounds with poor aqueous solubility.

“There are several advantages with this system,” Dr Alani said. “We can finally reach clinical levels of these polyphenols in the body. We can load both the compounds at one time to help control the cardiotoxicity of the cancer drug, and we can help the polyphenols accumulate in cancer cells where they have their own anticancer properties.”

In combination with doxorubicin

The investigators prepared mRQ micelles that were capable of retaining 1.1 mg/mL of resveratrol and 1.42 mg/mL of quercetin. They then tested mRQ in combination with doxorubicin in human ovarian cancer cells (SKOV-3) and rat cardiomyocytes (H9C2).

The team found that a resveratrol-quercetin-doxorubicin ratio of 10:10:1 was synergistic in SKOV-3 cells and antagonistic in H9C2 cells.

mRQ did not interfere with doxorubicin’s caspase activity in SKOV-3 cells but significantly decreased the activity in H9C2 cells. Likewise, there were no changes in the generation of reactive oxygen species in SKOV-3 cells, but there was significant scavenging in H9C2 cells.

The investigators also administered doxorubicin, with or without mRQ, to healthy mice and found that mRQ “conferred full cardioprotection.”

Dr Alani noted that previous research suggested resveratrol and quercetin are safe when given at high concentrations, but additional research is needed.

Patient receiving chemotherapy

Photo by Rhoda Baer

New research suggests the polyphenols resveratrol and quercetin could be used to augment treatment with the anthracycline doxorubicin.

Investigators found they could increase the bioavailability of resveratrol and quercetin using copolymers that make the compounds water soluble and allow for their injection into the blood stream.

The team then showed the compounds synergize with doxorubicin while also reducing cardiac toxicity.

Although doxorubicin has proven effective against lymphomas, leukemias, and other cancers, the drug can only be used for a limited time because it confers cardiotoxicity.

The co-administration of resveratrol and quercetin might allow for much more extensive use of doxorubicin, while at the same time improving its efficacy and demonstrating the polyphenols’ own anticancer properties, investigators said.

They described research supporting this idea in the Journal of Controlled Release.

“This has great potential to improve chemotherapeutic cancer treatment,” said Adam Alani, PhD, of Oregon State University in Portland.

“The co-administration of high levels of resveratrol and quercetin, in both in vitro and in vivo studies, shows that it significantly reduces the cardiac toxicity of [doxorubicin]. And these compounds have a synergistic effect that enhances the efficacy of the cancer drug, by sensitizing the cancer cells to the effects of the drug.”

Dr Alani said further research may demonstrate that these compounds can completely eliminate the cardiotoxicity of doxorubicin, as they scavenge the toxic free radicals produced by this drug.

It’s also possible, he said, that administration of these natural polyphenols could have value in cancer therapy by themselves or in combination with a wider range of other chemotherapeutic drugs.

Increasing bioavailability

Resveratrol is a natural compound found in foods such as grapes, red wine, green tea, berries, and dark chocolate. Quercetin reaches some of its highest natural levels in capers, some berries, and leafy greens.

When consumed via food or taken as supplements, these polyphenol compounds reach only a tiny fraction of the level that’s possible with direct injection. Such injection was not possible until Dr Alani and his colleagues adapted the use of polymeric micelles.

Specifically, the investigators combined resveratrol and quercetin in Pluronic F127 micelles (mRQ). Pluronics are triblock copolymers consisting of a polypropylene oxide chain flanked with 2 polyethylene oxide chains that can self-assemble into polymeric micelles. The micelles have hydrophobic cores that help solubilize compounds with poor aqueous solubility.

“There are several advantages with this system,” Dr Alani said. “We can finally reach clinical levels of these polyphenols in the body. We can load both the compounds at one time to help control the cardiotoxicity of the cancer drug, and we can help the polyphenols accumulate in cancer cells where they have their own anticancer properties.”

In combination with doxorubicin

The investigators prepared mRQ micelles that were capable of retaining 1.1 mg/mL of resveratrol and 1.42 mg/mL of quercetin. They then tested mRQ in combination with doxorubicin in human ovarian cancer cells (SKOV-3) and rat cardiomyocytes (H9C2).

The team found that a resveratrol-quercetin-doxorubicin ratio of 10:10:1 was synergistic in SKOV-3 cells and antagonistic in H9C2 cells.

mRQ did not interfere with doxorubicin’s caspase activity in SKOV-3 cells but significantly decreased the activity in H9C2 cells. Likewise, there were no changes in the generation of reactive oxygen species in SKOV-3 cells, but there was significant scavenging in H9C2 cells.

The investigators also administered doxorubicin, with or without mRQ, to healthy mice and found that mRQ “conferred full cardioprotection.”

Dr Alani noted that previous research suggested resveratrol and quercetin are safe when given at high concentrations, but additional research is needed.

Patient receiving chemotherapy

Photo by Rhoda Baer

New research suggests the polyphenols resveratrol and quercetin could be used to augment treatment with the anthracycline doxorubicin.

Investigators found they could increase the bioavailability of resveratrol and quercetin using copolymers that make the compounds water soluble and allow for their injection into the blood stream.

The team then showed the compounds synergize with doxorubicin while also reducing cardiac toxicity.

Although doxorubicin has proven effective against lymphomas, leukemias, and other cancers, the drug can only be used for a limited time because it confers cardiotoxicity.

The co-administration of resveratrol and quercetin might allow for much more extensive use of doxorubicin, while at the same time improving its efficacy and demonstrating the polyphenols’ own anticancer properties, investigators said.

They described research supporting this idea in the Journal of Controlled Release.

“This has great potential to improve chemotherapeutic cancer treatment,” said Adam Alani, PhD, of Oregon State University in Portland.

“The co-administration of high levels of resveratrol and quercetin, in both in vitro and in vivo studies, shows that it significantly reduces the cardiac toxicity of [doxorubicin]. And these compounds have a synergistic effect that enhances the efficacy of the cancer drug, by sensitizing the cancer cells to the effects of the drug.”

Dr Alani said further research may demonstrate that these compounds can completely eliminate the cardiotoxicity of doxorubicin, as they scavenge the toxic free radicals produced by this drug.

It’s also possible, he said, that administration of these natural polyphenols could have value in cancer therapy by themselves or in combination with a wider range of other chemotherapeutic drugs.

Increasing bioavailability

Resveratrol is a natural compound found in foods such as grapes, red wine, green tea, berries, and dark chocolate. Quercetin reaches some of its highest natural levels in capers, some berries, and leafy greens.

When consumed via food or taken as supplements, these polyphenol compounds reach only a tiny fraction of the level that’s possible with direct injection. Such injection was not possible until Dr Alani and his colleagues adapted the use of polymeric micelles.

Specifically, the investigators combined resveratrol and quercetin in Pluronic F127 micelles (mRQ). Pluronics are triblock copolymers consisting of a polypropylene oxide chain flanked with 2 polyethylene oxide chains that can self-assemble into polymeric micelles. The micelles have hydrophobic cores that help solubilize compounds with poor aqueous solubility.

“There are several advantages with this system,” Dr Alani said. “We can finally reach clinical levels of these polyphenols in the body. We can load both the compounds at one time to help control the cardiotoxicity of the cancer drug, and we can help the polyphenols accumulate in cancer cells where they have their own anticancer properties.”

In combination with doxorubicin

The investigators prepared mRQ micelles that were capable of retaining 1.1 mg/mL of resveratrol and 1.42 mg/mL of quercetin. They then tested mRQ in combination with doxorubicin in human ovarian cancer cells (SKOV-3) and rat cardiomyocytes (H9C2).

The team found that a resveratrol-quercetin-doxorubicin ratio of 10:10:1 was synergistic in SKOV-3 cells and antagonistic in H9C2 cells.

mRQ did not interfere with doxorubicin’s caspase activity in SKOV-3 cells but significantly decreased the activity in H9C2 cells. Likewise, there were no changes in the generation of reactive oxygen species in SKOV-3 cells, but there was significant scavenging in H9C2 cells.

The investigators also administered doxorubicin, with or without mRQ, to healthy mice and found that mRQ “conferred full cardioprotection.”

Dr Alani noted that previous research suggested resveratrol and quercetin are safe when given at high concentrations, but additional research is needed.

Thalassemia major

Low bioavailability of the amino acid arginine may contribute to cardiopulmonary dysfunction in patients with β-thalassemia, according to researchers.

Via previous work, the team found that arginine deficiency is a major factor in acute pain episodes in sickle cell disease.

With the current study, they discovered that arginase activity and concentration correlate with echocardiographic and cardiac-MRI measurements of cardiopulmonary function.

Claudia R. Morris, MD, of Emory University School of Medicine in Atlanta, Georgia, and her colleagues described this research in the British Journal of Haematology.

“We are finding that arginine dysregulation is an important hematologic mechanism beyond sickle cell disease,” Dr Morris said. “This new study shows that it plays a role in thalassemia patients as well and may contribute to cardiopulmonary dysfunction. Interventions aimed at restoring arginine bioavailability could be a promising area of focus for new therapeutics.”

Dr Morris and her colleagues noted that pulmonary hypertension (PH) is a common problem in patients with thalassemia. An elevated tricuspid-regurgitant jet-velocity (TRV) of 2.5 m/s or greater on Doppler echocardiography can identify patients with an increased risk of PH. But a right heart catheterization is required to confirm the condition.

The researchers wanted to provide a comprehensive description of the cardiopulmonary and biological profile of thalassemia patients at risk of developing PH. So they analyzed 27 patients with β-thalassemia.

Fourteen patients had an elevated TRV (≥ 2.5 m/s). According to echocardiography, these patients had a significantly larger right atrial size (P=0.03), left atrial size (P=0.002), left ventricular (LV) mass (P=0.03), and left septal-wall thickness (P=0.03) than patients with a TRV below 2.5 m/s.

According to MRI, patients with elevated TRV had significantly higher left atrial volume than patients with a TRV < 2.5 m/s (P=0.008).

Patients with an elevated TRV also had elevated lactate dehydrogenase (LDH) levels (P=0.03) and biomarkers of abnormal coagulation, including thrombin-antithrombin complex (P=0.04) and monoclonal prothrombin fragment 1.2 (P=0.02).

Patients with a TRV ≥ 2.5 m/s had significantly lower plasma arginine concentration (P<0.001) and biomarkers of global arginine bioavailability, including plasma arginine/ornithine ratio (P=0.01) and mean plasma global arginine bioavailability ratio (arginine/ornithine + citrulline ratio, P=0.04).

These patients also had significantly higher arginase concentration and activity than patients with TRV below 2.5 m/s (P=0.02).

These findings prompted the researchers to evaluate the relationship between arginase activity/concentration and clinical and laboratory markers of disease severity.

They found that arginase concentration was significantly correlated with several parameters of cardiovascular function, including left atrial volume (echo and MRI), right atrial volume (MRI), LV end systolic volume (echo and MRI), LV end diastolic volume (echo and MRI), LV mass (echo and MRI), and cardiac index (echo).

Arginase concentration was also significantly correlated with white blood cell count (P=0.03), plasma arginine (P=0.0002), arginine/ornithine (P=0.01) and arginine/ornithine + citrulline ratios (P=0.05), and hemoglobin (P=0.02), bilirubin (P=0.02), and LDH levels (P=0.001).

In multiple regression analysis, only cardiac index, bilirubin, and plasma arginine/ornithine ratio remained significantly associated with arginase concentration (P<0.05 for all).

Arginase activity was significantly correlated with several biomarkers of coagulation, including monoclonal prothrombin fragment 1.2 (P=0.04), thrombin-antithrombin complex (P=0.04), and tissue factor concentration (P=0.02).

Considering these results together, the researchers said it seems low arginine bioavailability contributes to cardiopulmonary dysfunction in patients with β-thalassemia.

Thalassemia major

Low bioavailability of the amino acid arginine may contribute to cardiopulmonary dysfunction in patients with β-thalassemia, according to researchers.

Via previous work, the team found that arginine deficiency is a major factor in acute pain episodes in sickle cell disease.

With the current study, they discovered that arginase activity and concentration correlate with echocardiographic and cardiac-MRI measurements of cardiopulmonary function.

Claudia R. Morris, MD, of Emory University School of Medicine in Atlanta, Georgia, and her colleagues described this research in the British Journal of Haematology.

“We are finding that arginine dysregulation is an important hematologic mechanism beyond sickle cell disease,” Dr Morris said. “This new study shows that it plays a role in thalassemia patients as well and may contribute to cardiopulmonary dysfunction. Interventions aimed at restoring arginine bioavailability could be a promising area of focus for new therapeutics.”

Dr Morris and her colleagues noted that pulmonary hypertension (PH) is a common problem in patients with thalassemia. An elevated tricuspid-regurgitant jet-velocity (TRV) of 2.5 m/s or greater on Doppler echocardiography can identify patients with an increased risk of PH. But a right heart catheterization is required to confirm the condition.

The researchers wanted to provide a comprehensive description of the cardiopulmonary and biological profile of thalassemia patients at risk of developing PH. So they analyzed 27 patients with β-thalassemia.

Fourteen patients had an elevated TRV (≥ 2.5 m/s). According to echocardiography, these patients had a significantly larger right atrial size (P=0.03), left atrial size (P=0.002), left ventricular (LV) mass (P=0.03), and left septal-wall thickness (P=0.03) than patients with a TRV below 2.5 m/s.

According to MRI, patients with elevated TRV had significantly higher left atrial volume than patients with a TRV < 2.5 m/s (P=0.008).

Patients with an elevated TRV also had elevated lactate dehydrogenase (LDH) levels (P=0.03) and biomarkers of abnormal coagulation, including thrombin-antithrombin complex (P=0.04) and monoclonal prothrombin fragment 1.2 (P=0.02).

Patients with a TRV ≥ 2.5 m/s had significantly lower plasma arginine concentration (P<0.001) and biomarkers of global arginine bioavailability, including plasma arginine/ornithine ratio (P=0.01) and mean plasma global arginine bioavailability ratio (arginine/ornithine + citrulline ratio, P=0.04).

These patients also had significantly higher arginase concentration and activity than patients with TRV below 2.5 m/s (P=0.02).

These findings prompted the researchers to evaluate the relationship between arginase activity/concentration and clinical and laboratory markers of disease severity.

They found that arginase concentration was significantly correlated with several parameters of cardiovascular function, including left atrial volume (echo and MRI), right atrial volume (MRI), LV end systolic volume (echo and MRI), LV end diastolic volume (echo and MRI), LV mass (echo and MRI), and cardiac index (echo).

Arginase concentration was also significantly correlated with white blood cell count (P=0.03), plasma arginine (P=0.0002), arginine/ornithine (P=0.01) and arginine/ornithine + citrulline ratios (P=0.05), and hemoglobin (P=0.02), bilirubin (P=0.02), and LDH levels (P=0.001).

In multiple regression analysis, only cardiac index, bilirubin, and plasma arginine/ornithine ratio remained significantly associated with arginase concentration (P<0.05 for all).

Arginase activity was significantly correlated with several biomarkers of coagulation, including monoclonal prothrombin fragment 1.2 (P=0.04), thrombin-antithrombin complex (P=0.04), and tissue factor concentration (P=0.02).

Considering these results together, the researchers said it seems low arginine bioavailability contributes to cardiopulmonary dysfunction in patients with β-thalassemia.

Thalassemia major

Low bioavailability of the amino acid arginine may contribute to cardiopulmonary dysfunction in patients with β-thalassemia, according to researchers.

Via previous work, the team found that arginine deficiency is a major factor in acute pain episodes in sickle cell disease.

With the current study, they discovered that arginase activity and concentration correlate with echocardiographic and cardiac-MRI measurements of cardiopulmonary function.

Claudia R. Morris, MD, of Emory University School of Medicine in Atlanta, Georgia, and her colleagues described this research in the British Journal of Haematology.

“We are finding that arginine dysregulation is an important hematologic mechanism beyond sickle cell disease,” Dr Morris said. “This new study shows that it plays a role in thalassemia patients as well and may contribute to cardiopulmonary dysfunction. Interventions aimed at restoring arginine bioavailability could be a promising area of focus for new therapeutics.”

Dr Morris and her colleagues noted that pulmonary hypertension (PH) is a common problem in patients with thalassemia. An elevated tricuspid-regurgitant jet-velocity (TRV) of 2.5 m/s or greater on Doppler echocardiography can identify patients with an increased risk of PH. But a right heart catheterization is required to confirm the condition.

The researchers wanted to provide a comprehensive description of the cardiopulmonary and biological profile of thalassemia patients at risk of developing PH. So they analyzed 27 patients with β-thalassemia.

Fourteen patients had an elevated TRV (≥ 2.5 m/s). According to echocardiography, these patients had a significantly larger right atrial size (P=0.03), left atrial size (P=0.002), left ventricular (LV) mass (P=0.03), and left septal-wall thickness (P=0.03) than patients with a TRV below 2.5 m/s.

According to MRI, patients with elevated TRV had significantly higher left atrial volume than patients with a TRV < 2.5 m/s (P=0.008).

Patients with an elevated TRV also had elevated lactate dehydrogenase (LDH) levels (P=0.03) and biomarkers of abnormal coagulation, including thrombin-antithrombin complex (P=0.04) and monoclonal prothrombin fragment 1.2 (P=0.02).

Patients with a TRV ≥ 2.5 m/s had significantly lower plasma arginine concentration (P<0.001) and biomarkers of global arginine bioavailability, including plasma arginine/ornithine ratio (P=0.01) and mean plasma global arginine bioavailability ratio (arginine/ornithine + citrulline ratio, P=0.04).

These patients also had significantly higher arginase concentration and activity than patients with TRV below 2.5 m/s (P=0.02).

These findings prompted the researchers to evaluate the relationship between arginase activity/concentration and clinical and laboratory markers of disease severity.

They found that arginase concentration was significantly correlated with several parameters of cardiovascular function, including left atrial volume (echo and MRI), right atrial volume (MRI), LV end systolic volume (echo and MRI), LV end diastolic volume (echo and MRI), LV mass (echo and MRI), and cardiac index (echo).

Arginase concentration was also significantly correlated with white blood cell count (P=0.03), plasma arginine (P=0.0002), arginine/ornithine (P=0.01) and arginine/ornithine + citrulline ratios (P=0.05), and hemoglobin (P=0.02), bilirubin (P=0.02), and LDH levels (P=0.001).

In multiple regression analysis, only cardiac index, bilirubin, and plasma arginine/ornithine ratio remained significantly associated with arginase concentration (P<0.05 for all).

Arginase activity was significantly correlated with several biomarkers of coagulation, including monoclonal prothrombin fragment 1.2 (P=0.04), thrombin-antithrombin complex (P=0.04), and tissue factor concentration (P=0.02).

Considering these results together, the researchers said it seems low arginine bioavailability contributes to cardiopulmonary dysfunction in patients with β-thalassemia.

Anopheles stephensi mosquito

Photo courtesy of the CDC

Repeat infection with malaria parasites might make mosquitoes more dangerous, according to a study published in PLOS Pathogens.

The research showed that individual Anopheles mosquitoes can accumulate infections with different strains of malaria parasites, an existing malaria infection makes mosquitoes more susceptible to a second infection, and infections reach higher densities when another strain is already present.

These phenomena could promote the spread of drug-resistant malaria, according to investigators.

Laura Pollitt, PhD, of the University of Edinburgh in the UK, and her colleagues conducted this research.

They wanted to determine if and how mosquitoes can be infected with different strains of Plasmodium parasites, how such heterogeneous parasites interact in the insects, and whether such interactions affect the transmission of malaria to vertebrate hosts.

The investigators set up cages of female Anopheles stephensi mosquitoes and allowed them, at defined times, to feed on mice infected with 2 different Plasmodium chabaudi strains—AJ and ER.

This study design allowed the team to examine how the presence of a co-infecting strain affects parasites that enter the vector first and second, and to test whether co-infection impacts mosquito survival.

The investigators found that mosquitoes can accumulate mixed-strain malaria infections after feeding on multiple hosts. And parasites have a greater chance of establishing a secondary infection if another Plasmodium strain is already present in a mosquito.

Moreover, the presence of the primary infection facilitated replication of the secondary infection while the first infection developed as normal. This resulted in doubly infected mosquitoes having substantially higher parasite loads.

The investigators noted that the large parasite numbers do not appear to kill the insects. And, because it is expected that mosquitoes carrying more parasites are more likely to transmit malaria to vertebrates, mosquitoes taking multiple infective bites might disproportionally contribute to malaria transmission.

This, in turn, would increase rates of mixed infections in vertebrate hosts, with implications for the evolution of parasite virulence and the spread of drug-resistant strains.

Anopheles stephensi mosquito

Photo courtesy of the CDC

Repeat infection with malaria parasites might make mosquitoes more dangerous, according to a study published in PLOS Pathogens.

The research showed that individual Anopheles mosquitoes can accumulate infections with different strains of malaria parasites, an existing malaria infection makes mosquitoes more susceptible to a second infection, and infections reach higher densities when another strain is already present.

These phenomena could promote the spread of drug-resistant malaria, according to investigators.

Laura Pollitt, PhD, of the University of Edinburgh in the UK, and her colleagues conducted this research.

They wanted to determine if and how mosquitoes can be infected with different strains of Plasmodium parasites, how such heterogeneous parasites interact in the insects, and whether such interactions affect the transmission of malaria to vertebrate hosts.

The investigators set up cages of female Anopheles stephensi mosquitoes and allowed them, at defined times, to feed on mice infected with 2 different Plasmodium chabaudi strains—AJ and ER.

This study design allowed the team to examine how the presence of a co-infecting strain affects parasites that enter the vector first and second, and to test whether co-infection impacts mosquito survival.

The investigators found that mosquitoes can accumulate mixed-strain malaria infections after feeding on multiple hosts. And parasites have a greater chance of establishing a secondary infection if another Plasmodium strain is already present in a mosquito.

Moreover, the presence of the primary infection facilitated replication of the secondary infection while the first infection developed as normal. This resulted in doubly infected mosquitoes having substantially higher parasite loads.

The investigators noted that the large parasite numbers do not appear to kill the insects. And, because it is expected that mosquitoes carrying more parasites are more likely to transmit malaria to vertebrates, mosquitoes taking multiple infective bites might disproportionally contribute to malaria transmission.

This, in turn, would increase rates of mixed infections in vertebrate hosts, with implications for the evolution of parasite virulence and the spread of drug-resistant strains.

Anopheles stephensi mosquito

Photo courtesy of the CDC

Repeat infection with malaria parasites might make mosquitoes more dangerous, according to a study published in PLOS Pathogens.

The research showed that individual Anopheles mosquitoes can accumulate infections with different strains of malaria parasites, an existing malaria infection makes mosquitoes more susceptible to a second infection, and infections reach higher densities when another strain is already present.

These phenomena could promote the spread of drug-resistant malaria, according to investigators.

Laura Pollitt, PhD, of the University of Edinburgh in the UK, and her colleagues conducted this research.

They wanted to determine if and how mosquitoes can be infected with different strains of Plasmodium parasites, how such heterogeneous parasites interact in the insects, and whether such interactions affect the transmission of malaria to vertebrate hosts.

The investigators set up cages of female Anopheles stephensi mosquitoes and allowed them, at defined times, to feed on mice infected with 2 different Plasmodium chabaudi strains—AJ and ER.

This study design allowed the team to examine how the presence of a co-infecting strain affects parasites that enter the vector first and second, and to test whether co-infection impacts mosquito survival.

The investigators found that mosquitoes can accumulate mixed-strain malaria infections after feeding on multiple hosts. And parasites have a greater chance of establishing a secondary infection if another Plasmodium strain is already present in a mosquito.

Moreover, the presence of the primary infection facilitated replication of the secondary infection while the first infection developed as normal. This resulted in doubly infected mosquitoes having substantially higher parasite loads.

The investigators noted that the large parasite numbers do not appear to kill the insects. And, because it is expected that mosquitoes carrying more parasites are more likely to transmit malaria to vertebrates, mosquitoes taking multiple infective bites might disproportionally contribute to malaria transmission.

This, in turn, would increase rates of mixed infections in vertebrate hosts, with implications for the evolution of parasite virulence and the spread of drug-resistant strains.

Revision of the Health Insurance Portability and Accountability Act (HIPAA) rules has prompted numerous questions about business associates (BAs) and business associate agreements (BAAs). Apparently there is confusion about exactly which businesses qualify as BAs and how your BAAs should be modified to reflect the new provisions.

The criteria for identifying BAs are admittedly vague: The act defines them as nonemployees, performing “functions or activities” on behalf of the “covered entity” (your practice) that involve “creating, receiving, maintaining, or transmitting” personal health information (PHI).

Clearly, answering and billing services, independent transcriptionists, hardware and software companies, and any other vendors involved in creating or maintaining your medical records always qualify as BAs. Other businesses may or may not qualify, depending on whether they need direct access to PHI in order to provide their service. These include practice management consultants, attorneys, companies that store or microfilm medical records, and record-shredding services.

Specialty pharmacies are seldom mentioned in the BA discussion, but they probably should be. Pharmaceutical manufacturers are increasingly using them as intermediaries for their products – particularly the more expensive ones, such as biologics. Many of them ship products directly to patients, for which they require home addresses and other personal information, and in order to file payment paperwork and claim forms, they usually request diagnoses and associated medical information. By any reasonable interpretation of the new rules, this makes them BAs, and you should have BAAs in place before allowing them to fill your prescriptions.

To further complicate the situation, manufacturers and insurers routinely compile information about the real world uses of their products. To that end, they often ask specialty pharmacies to provide them with any patient data that they collect. Under the new rules, patients may restrict any PHI shared with third parties when patients pay for the drugs or services themselves. Your specialty pharmacy BAA should include a provision noting that the pharmacy is forbidden from disclosing any data to pharmaceutical companies or insurers from patients who self-pay and request confidentiality.

Mail carriers, package delivery people, cleaning services, copier repairmen, bank employees, and the like are not considered BAs. While they might conceivably come in contact with PHI on occasion, they don’t need it to do their job. You are required to use “reasonable diligence” in limiting the PHI that these folks may encounter, but you do not need to enter into written BA agreements with them.

Independent contractors who work within your practice – aestheticians and physical therapists, for example – are not considered BAs either, and do not need to sign a BA agreement. Just train them, as you do your employees.

Another source of confusion is the provision in the new rules that makes BAs directly responsible for their own HIPAA violations. While this might seem to eliminate the need for BAAs entirely, unfortunately that is not the case. In fact, even more responsibility has been placed on physicians for confidentiality breaches committed by their BAs. It is not enough to simply have a BAA in place; you are expected to use “reasonable diligence” in monitoring the work of your BAs. While BAs and their subcontractors are responsible for their own actions, the primary responsibility remains with you. Furthermore, you now must assume the worst-case scenario. Previously, when PHI was compromised, you would have to notify affected patients (and the government) only if there was a “significant risk of financial or reputational harm”; but now, any incident involving patient records is assumed to be a breach, and must be reported. Failure to do so could subject your practice, as well as the contractor, to significant fines.

If you haven’t yet revised your Notice of Privacy Practices (NPP) to explain your relationships with BAs, and their status under the new rules, do it now. (You should have done it last September.) You need to explain the breach notification process too, as well as the new patient rights mentioned above. You must post your revised NPP in your office, and make copies available there, but you need not mail a copy to every patient.

Dr. Eastern practices dermatology and dermatologic surgery in Belleville, N.J. He is the author of numerous articles and textbook chapters, and is a longtime monthly columnist for Dermatology News.

Revision of the Health Insurance Portability and Accountability Act (HIPAA) rules has prompted numerous questions about business associates (BAs) and business associate agreements (BAAs). Apparently there is confusion about exactly which businesses qualify as BAs and how your BAAs should be modified to reflect the new provisions.

The criteria for identifying BAs are admittedly vague: The act defines them as nonemployees, performing “functions or activities” on behalf of the “covered entity” (your practice) that involve “creating, receiving, maintaining, or transmitting” personal health information (PHI).

Clearly, answering and billing services, independent transcriptionists, hardware and software companies, and any other vendors involved in creating or maintaining your medical records always qualify as BAs. Other businesses may or may not qualify, depending on whether they need direct access to PHI in order to provide their service. These include practice management consultants, attorneys, companies that store or microfilm medical records, and record-shredding services.

Specialty pharmacies are seldom mentioned in the BA discussion, but they probably should be. Pharmaceutical manufacturers are increasingly using them as intermediaries for their products – particularly the more expensive ones, such as biologics. Many of them ship products directly to patients, for which they require home addresses and other personal information, and in order to file payment paperwork and claim forms, they usually request diagnoses and associated medical information. By any reasonable interpretation of the new rules, this makes them BAs, and you should have BAAs in place before allowing them to fill your prescriptions.

To further complicate the situation, manufacturers and insurers routinely compile information about the real world uses of their products. To that end, they often ask specialty pharmacies to provide them with any patient data that they collect. Under the new rules, patients may restrict any PHI shared with third parties when patients pay for the drugs or services themselves. Your specialty pharmacy BAA should include a provision noting that the pharmacy is forbidden from disclosing any data to pharmaceutical companies or insurers from patients who self-pay and request confidentiality.

Mail carriers, package delivery people, cleaning services, copier repairmen, bank employees, and the like are not considered BAs. While they might conceivably come in contact with PHI on occasion, they don’t need it to do their job. You are required to use “reasonable diligence” in limiting the PHI that these folks may encounter, but you do not need to enter into written BA agreements with them.

Independent contractors who work within your practice – aestheticians and physical therapists, for example – are not considered BAs either, and do not need to sign a BA agreement. Just train them, as you do your employees.

Another source of confusion is the provision in the new rules that makes BAs directly responsible for their own HIPAA violations. While this might seem to eliminate the need for BAAs entirely, unfortunately that is not the case. In fact, even more responsibility has been placed on physicians for confidentiality breaches committed by their BAs. It is not enough to simply have a BAA in place; you are expected to use “reasonable diligence” in monitoring the work of your BAs. While BAs and their subcontractors are responsible for their own actions, the primary responsibility remains with you. Furthermore, you now must assume the worst-case scenario. Previously, when PHI was compromised, you would have to notify affected patients (and the government) only if there was a “significant risk of financial or reputational harm”; but now, any incident involving patient records is assumed to be a breach, and must be reported. Failure to do so could subject your practice, as well as the contractor, to significant fines.

If you haven’t yet revised your Notice of Privacy Practices (NPP) to explain your relationships with BAs, and their status under the new rules, do it now. (You should have done it last September.) You need to explain the breach notification process too, as well as the new patient rights mentioned above. You must post your revised NPP in your office, and make copies available there, but you need not mail a copy to every patient.

Dr. Eastern practices dermatology and dermatologic surgery in Belleville, N.J. He is the author of numerous articles and textbook chapters, and is a longtime monthly columnist for Dermatology News.

Revision of the Health Insurance Portability and Accountability Act (HIPAA) rules has prompted numerous questions about business associates (BAs) and business associate agreements (BAAs). Apparently there is confusion about exactly which businesses qualify as BAs and how your BAAs should be modified to reflect the new provisions.

The criteria for identifying BAs are admittedly vague: The act defines them as nonemployees, performing “functions or activities” on behalf of the “covered entity” (your practice) that involve “creating, receiving, maintaining, or transmitting” personal health information (PHI).

Clearly, answering and billing services, independent transcriptionists, hardware and software companies, and any other vendors involved in creating or maintaining your medical records always qualify as BAs. Other businesses may or may not qualify, depending on whether they need direct access to PHI in order to provide their service. These include practice management consultants, attorneys, companies that store or microfilm medical records, and record-shredding services.

Specialty pharmacies are seldom mentioned in the BA discussion, but they probably should be. Pharmaceutical manufacturers are increasingly using them as intermediaries for their products – particularly the more expensive ones, such as biologics. Many of them ship products directly to patients, for which they require home addresses and other personal information, and in order to file payment paperwork and claim forms, they usually request diagnoses and associated medical information. By any reasonable interpretation of the new rules, this makes them BAs, and you should have BAAs in place before allowing them to fill your prescriptions.

To further complicate the situation, manufacturers and insurers routinely compile information about the real world uses of their products. To that end, they often ask specialty pharmacies to provide them with any patient data that they collect. Under the new rules, patients may restrict any PHI shared with third parties when patients pay for the drugs or services themselves. Your specialty pharmacy BAA should include a provision noting that the pharmacy is forbidden from disclosing any data to pharmaceutical companies or insurers from patients who self-pay and request confidentiality.

Mail carriers, package delivery people, cleaning services, copier repairmen, bank employees, and the like are not considered BAs. While they might conceivably come in contact with PHI on occasion, they don’t need it to do their job. You are required to use “reasonable diligence” in limiting the PHI that these folks may encounter, but you do not need to enter into written BA agreements with them.

Independent contractors who work within your practice – aestheticians and physical therapists, for example – are not considered BAs either, and do not need to sign a BA agreement. Just train them, as you do your employees.

Another source of confusion is the provision in the new rules that makes BAs directly responsible for their own HIPAA violations. While this might seem to eliminate the need for BAAs entirely, unfortunately that is not the case. In fact, even more responsibility has been placed on physicians for confidentiality breaches committed by their BAs. It is not enough to simply have a BAA in place; you are expected to use “reasonable diligence” in monitoring the work of your BAs. While BAs and their subcontractors are responsible for their own actions, the primary responsibility remains with you. Furthermore, you now must assume the worst-case scenario. Previously, when PHI was compromised, you would have to notify affected patients (and the government) only if there was a “significant risk of financial or reputational harm”; but now, any incident involving patient records is assumed to be a breach, and must be reported. Failure to do so could subject your practice, as well as the contractor, to significant fines.

If you haven’t yet revised your Notice of Privacy Practices (NPP) to explain your relationships with BAs, and their status under the new rules, do it now. (You should have done it last September.) You need to explain the breach notification process too, as well as the new patient rights mentioned above. You must post your revised NPP in your office, and make copies available there, but you need not mail a copy to every patient.

Dr. Eastern practices dermatology and dermatologic surgery in Belleville, N.J. He is the author of numerous articles and textbook chapters, and is a longtime monthly columnist for Dermatology News.